Potential Value of Plasma Amyloid-β, Total Tau, and Neurofilament Light for Identification of Early Alzheimer's Disease.

ACS Chem Neurosci

Department of Neurology, Affiliated ZhongDa Hospital, School of Medicine , Southeast University, Nanjing , Jiangsu 210009 , China.

Published: August 2019

The objective of the study was to explore the potential value of plasma indicators for identifying amnesic mild cognitive impairment (aMCI) and determine whether levels of plasma indicators are related to the performance of cognitive function and brain tissue volumes. In total, 155 participants (68 aMCI patients and 87 health controls) were recruited in the present cross-sectional study. The levels of plasma amyloid-β (Aβ) 40, Aβ42, total tau (t-tau), and neurofilament light (NFL) were measured using an ultrasensitive quantitative method. Machine learning algorithms were performed for establishing an optimal model of identifying aMCI. Compared with healthy controls, Aβ40 and Aβ42 levels were lower and NFL levels were higher in plasma of aMCI patients with an exception of t-tau levels. In aMCI patients, the higher plasma Aβ40 levels were correlated with the impaired episodic memory and negative correlations were observed between plasma t-tau levels and global cognitive function and gray matter (GM) volume. In addition, the higher plasma NFL levels were correlated with reduced hippocampus volume and total GM volume of the left inferior and middle temporal gyrus. An integrated model included clinical features, hippocampus volume, and plasma Aβ42 and NFL and had the highest accuracy for detecting aMCI patients (accuracy, 74.2%). We demonstrated that plasma Aβ40, Aβ42, t-tau, and NFL may be useful to identify aMCI and correlate with cognitive decline and brain atrophy. Among these plasma indicators, Aβ42 and NFL are more valuable as key members of a peripheral biomarker panel to detect aMCI.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acschemneuro.9b00095DOI Listing

Publication Analysis

Top Keywords

amci patients
16
plasma indicators
12
higher plasma
12
plasma
10
potential plasma
8
plasma amyloid-β
8
total tau
8
neurofilament light
8
amci
8
levels
8

Similar Publications

Background: Continuous speech analysis is considered as an efficient and convenient approach for early detection of Alzheimer's Disease (AD). However, the traditional approach generally requires human transcribers to transcribe audio data accurately. This study applied automatic speech recognition (ASR) in conjunction with natural language processing (NLP) techniques to automatically extract linguistic features from Chinese speech data.

View Article and Find Full Text PDF

Clinical Manifestations.

Alzheimers Dement

December 2024

Hallym University, Chuncheon, Gangwon-do, Korea, Republic of (South).

Background: In patients with mild cognitive impairment (MCI), the presence or absence of memory deficits is associated with divergent clinical presentations, etiologies, and prognostic outcomes. These differences may also manifest in additional neurologic signs beyond cognitive impairments and are often reflected in distinct magnetic resonance imaging (MRI) profiles. Gait is one of the clinical characteristics that reflects brain function along with cognitive function.

View Article and Find Full Text PDF

Background: Visual Mental Imagery (VMI) is the ability to represent stimuli in the mind without sensory visual input. Previous studies have shown alterations in visual imagery in Alzheimer's disease (AD). However, VMI has not been investigated in the AD prodromal stage, i.

View Article and Find Full Text PDF

Introduction: Hippocampal hyperactivity is a hallmark of prodromal Alzheimer's disease (AD) that predicts progression in patients with amnestic mild cognitive impairment (aMCI). AGB101 is an extended-release formulation of levetiracetam in the dose range previously demonstrated to normalize hippocampal activity and improve cognitive performance in aMCI. The HOPE4MCI study was a 78-week trial to assess the progression of MCI due to AD.

View Article and Find Full Text PDF

Longitudinal synaptic loss versus tau Braak staging in amnestic mild cognitive impairment.

Alzheimers Dement

December 2024

Nuclear Medicine and Molecular Imaging, Imaging and Pathology, KU Leuven, Leuven, Belgium.

Introduction: The longitudinal progression of synaptic loss in Alzheimer's disease (AD) and how it is affected by tau pathology remains poorly understood.

Methods: Thirty patients with amnestic mild cognitive impairment (aMCI) and 26 healthy controls underwent cognitive evaluations and tau, synaptic vesicle protein 2A (SV2A), and amyloid positron emission tomography. Twenty-one aMCI underwent 2-year follow-up (FU) investigations.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!